Radiation therapy equipment developer RefleXion Medical has announced a clinical collaboration with Merck to evaluate the safety and efficacy of Keytruda (pembrolizumab) in combination with RefleXion's biology-guided radiotherapy (BgRT) in multiple late-stage cancers, including non-small cell lung cancer.
Two randomized controlled clinical trials will be conducted to determine whether treating multiple tumors with BgRT, a form of external-beam radiotherapy in development, is safe and amplifies Keytruda's therapeutic effect. The RefleXion X1 machine with BgRT is designed to overcome the technical limitations that restrict radiotherapy delivery to one or two sites of disease, according to RefleXion.
